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the patients is 61 years, with these patients presenting cancer for
an average of 4 years. Eighty-nine percent of the patients use
capecitabine as monotherapy, and the rest use it combined with
injectable treatments. Comparing capecitabine with injectable
regimens, 89% of the studied subjects prefer the oral treatment.
Capecitabine is best evaluated than the injectable treatments in
the attributes: practicability, freedom, quality of life, efﬁcacy and
side effects. Treatments were assessed in a similar way about the
item cost. Approximately third quarters consider capecitabine as
efﬁcient; such rate is slightly higher than the observed for inject-
able chemotherapy: 75% vs. 58%. CONCLUSION: Capecitab-
ine is largely approved by its users, with 89% of them preferring
it in comparison with the injectable treatments. The oral chemo-
therapy has as positive differences, in the perception of its users,
practicability and freedom.
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OBJECTIVE: Elderly patients are underrepresented in oncology
trials and may be at higher risk of toxicity with less than optimal
quality of life compared with younger patients. The Phase III
TARGET clinical trial showed that sorafenib signiﬁcantly pro-
longed progression-free survival (PFS) compared with placebo
(P < 0.000001) in patients with advanced renal cell carcinoma
(RCC). This retrospective analysis of sorafenib in advanced
RCC patients from the pivotal TARGET trial compared patient
reported outcomes (PRO) in young and elderly patients.
METHODS: This subgroup analysis examined the PRO in
elderly (>=70 years of age) and young patients (<70 years of age)
for sorafenib and placebo. PRO was assessed at baseline and day
1 of each cycle using Functional Assessment of Cancer Therapy-
General (FACT-G) and FACT-Kidney Cancer Symptom Index
(FKSI). Descriptive statistics compared the proportion of patients
with a clinically meaningful change (4 point change) in total
scores of FKSI and Physical Well Being (PWB) from baseline.
Time to health status deterioration (4 point drop in total FKSI
scores or PWB scores of FACT-G) was assessed using Cox-
proportional Hazards model. RESULTS: A greater proportion of
patients in the sorafenib-treated group had improved or stable
symptom response and physical functioning in later cycles of
treatment, irrespective of age. Sorafenib delayed median time to
health status deterioration (as measured by FKSI questionnaire)
compared to placebo in elderly patients (121 days vs. 85 days)
The median time to health status deterioration as measured by
PWB domain of FACT-G was also longer for sorafenib compared
to placebo among elderly patients (126 vs. 84 days). A similar
trend was observed in younger patients. CONCLUSION: When
compared with placebo, elderly patients with advanced RCC
receiving sorafenib had PROs similar to those of young patients
receiving the same treatment, with both groups maintaining their
quality of life longer on sorafenib.
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OBJECTIVE: According to INCA (National Cancer Institute of
Brazil) estimates, colorectal cancer is the ﬁfth most common type
of cancer in the population; otherwise, it is the thirrd leading type
of tumor to cause death. The objective of this research is to assess
the knowledge of the Brazilian population about colorectal
cancer, its risks and diagnosis. METHODS: Quantitative study
performed through personal and individual interviews. A repre-
sentative sample of the study population (N = 600) was used.
People over 30 years old were interviewed. A 10-item structured
questionnaire was used. RESULTS: The study showed that 70%
of the population consider themselves as informed about cancer.
When asked about which would be the 3 most common types of
cancer, the main answers given were: 66% breast, 46% cervix,
42% prostate, 16% skin, and 15% lung. The colorectal cancer
was not mentioned by any subject in this question. Fifty-seven
percent of the population had never heard about colorectal
cancer. Among the 43% who had already heard about this type
of tumor, 76% didn’t know what were the symptoms and pre-
vention measures for this disease. Only 18% of the subjects over
50 years old have already undergone diagnostic tests for colorec-
tal cancer. CONCLUSION: Colorectal cancer is known for only
43% of the Brazilian population, which does not identify it as
one of the main tumors causing death in the country. In addition,
76% of the subjects who have already heard about this type of
cancer do not know the diagnostic and prevention methods for
this tumor. Only 18% of the population over 50 years old has
already undergone diagnostic tests for this type of cancer. These
results show that information campaigns about cancer could
render a better knowledge of the disease, which could result, in
the future, in early diagnosis, enabling a higher chance of cure
for patients.
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OBJECTIVE: Certain recent policy changes have mandated
ESA initiation at Hb < 10 g/dL. Real world clinical and eco-
nomic outcomes data associated with this change have not
been reported for the two FDA-approved ESAs for this popu-
lation [epoetin alfa (EPO) and darbepoetin alfa (DARB)].
METHODS: Data drawn between 12/03–11/07 from 55 U.S.
oncology clinics from the Dosing and Outcomes Study of
Erythropoietic Stimulating Therapies (D.O.S.E.) registry were
assessed. Patients were included if they were initiated on ESAs
with a BL Hb < 10 g/dL, age 18 years, and received 2 doses
of either EPO or DARB. Outcomes assessed included transfu-
sion utilization, Hb at Weeks 4, 8, 12 and 16 after ESA initia-
tion, and cumulative ESA doses with associated cost (based on
11/2007 wholesale acquisition cost). RESULTS: A total of 384
patients (168 EPO, 216 DARB) were identiﬁed. BL character-
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